---
layout: post
title: "Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Sickle Cell Disease"
date: 2026-02-05 18:56:44 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-19284
original_published: 2023-09-07 00:00:00 +0000
significance: 8.00
---

# Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Sickle Cell Disease

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** September 07, 2023 00:00 UTC
**Document Number:** 2023-19284

## Summary

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. On October 31, 2023, the Committee will discuss and make recommendations on biologics license application (BLA) 125787 from Vertex Pharmaceuticals, Inc. for exagamglogene autotemcel (exa-cel). The applicant has requested an indication for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso- occlusive crises. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/09/07/2023-19284/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establishment-of-a-public)
- API: https://www.federalregister.gov/api/v1/documents/2023-19284

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
